| NEWSLETTER:
MEMOTEXT NOTES |
| Please
select an issue. |
 |
Volume
5 | Issue
Three
Smith & Nephew and MEMOTEXT Launch the EXOGEN Connects Fracture
Treatment Adherence Program. |
|
Volume
5 | Issue
Two
Johns Hopkins study demonstrates 16% increase in patient
adherence using MEMOTEXT and Microsoft HealthVault in the
first randomized clinical trial of its kind in North America. |
|
Volume
5 | Issue
One
Strategic alliance with hcCatalyst and collaberation with
George Brown College. |
|
Volume
4 | Issue
Five
Season's Greetings. A new intervention. |
|
Volume
4 | Issue
Four
Canadian based Chronic Kidney Disease (CKD) program assessing
self efficacy and patient literacy. |
|
Volume
4 | Issue
Three
High cholesterol and hypertension |
|
Volume
4 | Issue
Two
Early recognition of diabetes complications |
|
Volume
4 | Issue
One
Patient Adherence Solutions |
|
Volume
3 | Issue
Five
8th Annual CBI Patient Compliance Adherence and Persistency
Summit |
|
Volume
3 | Issue
Four
MEMOTEXT & John Hopkins University's Wilmer Eye Institute
to use MEMOTEXT technology. Launch of MEMOTEXT Adherence
Innovations Blog. |
|
Volume
3 | Issue
Three
MEMOTEXT & Trillium Health study the effects of Voice
and SMS reminders on the treatment and monitoring of patients
with Type II diabetes. |
|
Volume
3 | Issue
Two
MEMOTEXT & Biogen Idec Canada Announce Ground-Breaking
Partnership to help patients with Multiple Sclerosis. |
|
Volume
3 | Issue
One
Synapse Group of USA and Canada provides scientific communications
and strategic direction to MEMOTEXT moving towards higher
standards of excellence in interactive health communications.
|
|
Volume
2 | Issue
Five
There is no Pill for Non-Adherence: Though dangerously wide
in scope and scale, medication non-compliance issues do
not yet appear to be top priority for health organizations
and stakeholders. |
|
Volume
2 | Issue
Four
Telephone-Linked Care Highly Effective at Modifying Health
Behavior: Journal of Medical Systems Summary |
|
Volume
1 | Issue
Three
In a recent discussion with Meena Bhogal, Sr. Product
Manager, Contraceptive Portfolio, Organon Canada Ltd.,
Schering Plough, we asked how the RemindMeToday program
is doing and whether MEMOTEXT has delivered on its promises.
|
|
Volume
1 | Issue
Two
As part of its expanded personalized adherence solution,
MEMOTEXT announces the release of MemotextPRO, a telephone-based
Patient Reported Outcomes (PRO) initiative. MemotextPRO
uses Speech-to-Text technology with professional transcription
validation. RemindMeToday.ca medication adherence program
achieves 91% retention. |
|
Volume
1 | Issue
One
Organon Canada and MEMOTEXT launch the RemindMeToday.ca
program targeted at users of the Linessa and NuvaRing contraceptive
brands. |
